No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Xofigo (radium Ra 223 dichloride) is a radiopharmaceutical used to treat prostate cancer that has spread to the bones. It is a targeted alpha therapy, meaning it emits radiation that is absorbed by the cancer cells, while sparing healthy tissue. Xofigo is administered intravenously and works by targeting and killing cancer cells in the bones. It is used in combination with other treatments, such as hormone therapy, to reduce pain and improve quality of life.
Xofigo is approved by the US Food and Drug Administration (FDA) for the treatment of prostate cancer that has spread to the bones. It is also approved in Europe and other countries.
The Xofigo market is composed of pharmaceutical companies that develop and market radiopharmaceuticals for the treatment of prostate cancer. Companies in this market include Bayer, Algeta, Advanced Accelerator Applications, and Actinium Pharmaceuticals. Show Less Read more
